

May 15, 2024



Milind Talegaonkar
Company Secretary & Compliance Officer
Eris Lifesciences Ltd.
8th floor, Commerce House IV,
Beside Shall Petrol Pump, 100 Feet Road,
Prahladnagar, Ahmedabad, Gujarat - 380015
Tel.: 079-48903474
Fax.: 079-48903474

Dear Sir,

Sub: Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


We refer to our letter dated December 18, 2023 wherein we had mentioned that as on December 15, 2023, the aggregate holding of the Schemes of HDFC Mutual Fund in "Eris Lifesciences Ltd" ("The Company") was 5.13% of the paid up equity share capital of the Company (Paid up Equity Share Capital being Rs. 13,60,23,248/- comprising 13,60,23,248 Equity Shares of Rs. 1/- each).

Further, in accordance with the captioned regulation and other applicable laws / regulations, if any, we wish to inform you that there has been an **increase** in the shareholding of the Company by the Schemes of HDFC Mutual Fund by **2.00%** as of May 14, 2024. As on May 14, 2024 the aggregate holding of the Schemes of HDFC Mutual Fund in the Company is **7.13%** of the paid up equity share capital of the Company (Paid up Equity Share Capital being Rs. 13,60,28,280/- comprising 13,60,28,280 Equity Shares of Rs. 1/- each).

As per Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 please find enclosed the details of change in the shareholding in the prescribed format enclosed as **Annexure 1**.

Kindly acknowledge receipt of the same.

Thanking you,
Yours faithfully,
For **HDFC Asset Management Company Limited**


MS Dinesh Bhakade
Deputy Vice President - Compliance

Encl: As above

CC:

Listing Department National Stock Exchange of India Ltd. Exchange Plaza, Bandra - Kurla Complex Bandra (E), Mumbai – 400 051. Tel.: 022- 2659 8190 Fax: 022- 2659 8191	Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001. Fax: 022- 2272 3121
---	---



Annexure-1



Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Eris Lifesciences Ltd		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	HDFC Mutual Fund: HDFC Trustee Company Limited A/c – HDFC S&P BSE 500 ETF HDFC S&P BSE 500 INDEX FUND HDFC Large and Mid Cap Fund HDFC Multi Cap Fund HDFC Pharma and Healthcare Fund HDFC Hybrid Equity Fund HDFC NIFTY SMALLCAP 250 ETF HDFC NIFTY SMALLCAP 250 INDEX FUND HDFC Small Cap Fund		
Whether the acquirer belongs to Promoter/ Promoter group	NO		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/ voting capital wherever applicable (*)	% w.r.t. total diluted share/ voting capital of the TC (**)
Before the acquisition under consideration, holding of :			
a) Shares carrying voting rights	69,75,299	5.13	N.A
b) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	0	0	N.A
c) Voting rights (VR) otherwise than by shares	0	0	N.A
d) Warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0	0	N.A
e) Total (a+b+c+d)	69,75,299	5.13	N.A
Details of Acquisition/Sale:			
a) Shares carrying voting rights acquired/sold	27,21,065	2.00	N.A
b) VRs acquired /sold otherwise than by shares	0	0	N.A
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	0	0	N.A



Annexure-1



**Disclosures under Regulation 29(2) of
SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

d) Shares encumbered/invoked/released by the acquirer	0	0	N.A
e) Total (a+b+c+/-d)	27,21,065	2.00	N.A
<u>After the Acquisition/Sale, holding of:</u>			
a) Shares carrying voting rights	96,96,364	7.13	N.A
b) Shares encumbered with the acquirer	0	0	N.A
c) VRs otherwise than by shares	0	0	N.A
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition.	0	0	N.A
e) Total (a+b+c+d)	96,96,364	7.13	N.A
Mode of acquisition/sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market		
Date of <u>acquisition/sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable</u>	May 14, 2024		
Equity share capital / total voting capital of the TC before the said acquisition/sale	Rs. 13,60,23,248/- comprising 13,60,23,248 equity shares of Rs. 1/- each.		
Equity share capital/ total voting capital of the TC after the said acquisition/sale	Rs. 13,60,28,280/- comprising 13,60,28,280 equity shares of Rs. 1/- each.		
Total diluted share/voting capital of the TC after the said acquisition/sale	N.A.		

(*) Total share capital/ voting capital has been taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For HDFC Asset Management Company Limited
(Investment Manager for the Schemes of HDFC Mutual Fund)


Dinesh Bhakade
Deputy Vice President - Compliance

Place: Mumbai
Date: May 15, 2024

